-
Interpretation of immune cytokines: the role of IL-18 and drug research progress A recent review
Time of Update: 2023-01-07
Fig. 1 Cell source and signal transduction mechanism of interleukin 18 Monoclonal antibodies and drugs targeting IL-18 Given IL-18's role in inflammation, targeting IL-18 appears to be a potential treatment.
Currently, a single-blind, randomized, placebo-controlled Phase 1 trial of human monoclonal antibody GSK1070806 is underway for inflammatory bowel disease (IBD).
-
Under the boom of pharmaceutical companies deploying AI, a number of companies have begun to usher in new breakthroughs
Time of Update: 2023-01-05
【Pharmaceutical Network Market Analysis】In recent years, the layout of AI by pharmaceutical companies has become an industry boom, especially with the help of AI, drug discovery and preclinical stage
-
Neurology: Clinical and structural manifestations in patients with pathological dystonia: descriptive and quantitative analysis of published cases
Time of Update: 2022-09-30
Latent analyses then investigated whether patients could be divided into subgroups based on the location of the lesion and the areas of the body affected by dystonia.
-
Shaping high-quality food industry with standardization strategy
Time of Update: 2022-09-01
The progress of the problem, the role of standardization on the high-quality development of the food industry and international trade, the application of rapid inspection technology, etc.
-
6 provinces form a Chinese patent medicine centralized procurement alliance, and the large-scale Chinese patent medicine alliance procurement registration begins
Time of Update: 2022-05-27
On March 17, the Guangdong Provincial Drug Trading Center issued the "Notice on Viewing Information about Guangdong Alliance Qingkailing and other Chinese patent medicines for centralized procurement
-
Keji Pharmaceutical's CT041 completes the first patient in China's confirmatory phase II clinical trial and is mainly enrolled in the treatment of advanced gastric cancer/esophagogastric junction
Time of Update: 2022-04-27
On March 23, 2022, Keji Pharmaceutical announced that CT041, the company's self-developed CAR-T cell candidate product, completed the first patient enrollment in China's confirmatory phase II clinical trial at Peking University Cancer Hospital.
-
The State Food and Drug Administration revises the instructions for arbidol preparations
Time of Update: 2022-02-20
1. The marketing authorization holders of the above-mentioned drugs should report to the State Drug Administration before April 12, 2022 in accordance with the relevant regulations such as the "Administrative Measures for Drug Registration", and in accordance with the requirements for the revision of the instructions for arbidol preparations (see attachment).
-
How Triclosan, Found in Many Consumer Products, Triggers Gut Damage
Time of Update: 2022-01-24
"By identifying the culprit bacteria, new ways of diagnosing, preventing and treating inflammatory bowel disease could be developed," said study author Matthew Redinbo, chemistry and chemist at UNC-Chapel Hill College of Arts and Sciences and UNC School of Medicine.
-
Nature Sub-Journal: LINC00842 promotes the malignant progression of pancreatic cancer through metabolic remodeling
Time of Update: 2021-09-06
For example, lincRNAs can recruit transcription factors to regulate the expression of genes involved in metabolism; they can regulate post-translational modifications of metabolism-related proteins, or they can be used as scaffolds or decoys to promote the interaction between metabolic enzymes .
LINC00842 inactivates transcription co-regulator PGC-1α to promote pancreatic cancer malignancy through metabolic remodelling.
-
Professor Song Yong: ALK-positive advanced NSCLC, you need to understand these developments
Time of Update: 2021-08-08
Professor Song Yong from the Department of Respiratory Diseases of Nanjing University Jinling Hospital and the Institute of Respiratory Diseases of Nanjing University introduced the current status and prospects of ALK-positive advanced non-small cell lung cancer (NSCLC) treatment in detail at the meeting .
-
Employee medical insurance fund expenditures increased by 1.6%, 390,000 pharmacies affected
Time of Update: 2021-06-22
150 billion yuan, of which the cumulative balance of employee medical insurance personal accounts was 10,096 100 million yuan .
150 billion yuan, of which the cumulative balance of employee medical insurance personal accounts was 10,096 100 million yuan .
-
After Biotech’s failure, the domestic Trop-2 ADC drug reported to be launched
Time of Update: 2021-06-02
On May 12, the CDE official website showed that Genting Pharmaceuticals submitted a listing application for Trop-2 ADC product-Trodelvy (gosartuzumab for injection) for metastatic triple-negative breast cancer that has received at least 2 therapies in the past (MTNBC) Adult patients.
-
Lancet Sub-Journal: First clinical evidence that drug-resistant malaria mutations are associated with delayed parasite clearance
Time of Update: 2021-04-22
Studies have found that in Africa, mutations are related to delayed clearance of parasites in children with malaria treated with common penicillin combination therapy ( ACTs ) .
-
Jiangxi has implemented a number of measures to promote the price reduction of imported drugs
Time of Update: 2021-02-18
Jiangxi Province Pharmaceutical Procurement Service Center issued "on the implementation of imported drugs and anti-cancer drugs price declaration notice", requiring imported drugs to take the initiative to reduce prices, otherwise cancel the procurement qualification; the province noted that the drugs involved in the 2015 National Drug Price Negotiations and the 2017 National Health Insurance Directory Access Negotiations are purchased online in accordance with the payment standards set by the State.
-
The listing application for Luspatercept, an innovative drug for blood diseases, was reviewed as a priority by CDE
Time of Update: 2021-02-12
"Luspatercept is the first innovative blood disease drug in China to be included in the priority review after submitting data from overseas clinical trials to CDE," said Dr. Cai Xuexuan, Vice President of Global Research and Development and Head of Research and Development in China.
